PainReform's New Manufacturing Process Achieves 18-Month Stability Of PRF-110 At Room Temperature
Author: Benzinga Newsdesk | August 01, 2024 08:39am
PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company's new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This stability study is ongoing and marks a significant achievement for PainReform.
Posted In: PRFX